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Abstract: Loss of the tumor suppressor phosphatase and tensin homologue deleted on chromosome
10 (PTEN), which negatively regulates the PI3K–AKT–mTOR pathway, is strongly linked to advanced
prostate cancer progression and poor clinical outcome. Accordingly, several therapeutic approaches
are currently being explored to combat PTEN-deficient tumors. These include classical inhibition of the
PI3K–AKT–mTOR signaling network, as well as new approaches that restore PTEN function, or target
PTEN regulation of chromosome stability, DNA damage repair and the tumor microenvironment.
While targeting PTEN-deficient prostate cancer remains a clinical challenge, new advances in the
field of precision medicine indicate that PTEN loss provides a valuable biomarker to stratify prostate
cancer patients for treatments, which may improve overall outcome. Here, we discuss the clinical
implications of PTEN loss in the management of prostate cancer and review recent therapeutic
advances in targeting PTEN-deficient prostate cancer. Deepening our understanding of how PTEN
loss contributes to prostate cancer growth and therapeutic resistance will inform the design of future
clinical studies and precision-medicine strategies that will ultimately improve patient care.
Keywords: PTEN; PI3K; targeted therapy; prostate cancer
1. Introduction
Prostate cancer is the second most frequently diagnosed male cancer worldwide, with over 1
million new cases recorded each year globally [1]. Although most men will not die from their disease,
prostate cancer is a leading cause of male cancer-associated deaths, accounting for >350,000 deaths
annually world-wide [1]. The primary cause of prostate cancer death is the emergence of incurable
metastatic and castrate-resistant disease that is resistant to current treatment regimens, such as
androgen-deprivation therapy (ADT) and chemotherapy, emphasizing the demand for new therapeutic
strategies. In an emerging era of precision medicine, a comprehensive understanding of the molecular
drivers of aggressive prostate cancer could improve patient outcomes through the tailored selection of
targeted therapies, and identify patient populations with indolent, localized prostate cancer that are
at risk of either developing aggressive forms of the disease or of being overtreated with potentially
life-altering treatments.
Loss of the tumor suppressor PTEN is commonly observed in patients with aggressive, hard-to-treat
prostate cancer. Although the frequency of PTEN loss in patients with prostate cancer varies between
studies, largely owing to differences in the methodological approaches used, recent studies involving
large prostate cancer patient cohorts have indicated that PTEN is lost in approximately 15–20% of
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primary prostate cancers [2–5]. A higher frequency of PTEN loss is observed in more aggressive stages
of the disease including castration-resistant prostate cancers (CRPC) and metastatic disease, with PTEN
lost in 40–60% of these cases [2–6]. The most common cause of functional PTEN loss in prostate
cancer is genomic homozygous deletion of PTEN. However, several other mechanisms have also been
reported, including inactivating somatic mutations (predominantly frameshift or non-sense truncating
mutations), suppression of PTEN-targeting microRNAs (miRNAs) and inactivating post-translational
modifications (e.g., phosphorylation and ubiquitylation) [7–11]. Infrequent epigenetic silencing via
methylation of the PTEN promoter has also been observed in patients with prostate cancer [10,12,13].
Under normal physiological conditions, PTEN antagonizes phosphatidylinositol 3-kinase
(PI3K) signaling through its role as a lipid phosphatase by converting phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), a lipid secondary messenger produced by PI3K, back to
phosphatidylinositol (4,5)-bisphosphate (PIP2). Consequently, PTEN inhibits PIP3-mediated cellular
events, including protein kinase B (PKB/AKT) and phosphoinositide-dependent kinase 1 (PDK1)
signaling [14]. Functional loss of PTEN results in the accumulation of PIP3, which subsequently
leads to unchecked PIP3 signaling that promotes oncogenic cellular events, including increased cell
proliferation, survival and migration. To this end, PIP3 recruits PH domain-containing substrates to the
membrane, such as AKT, which regulates a plethora of signaling components, including mammalian
target of rapamycin (mTOR), glycogen synthase kinase 3 beta (GSK3β) and Forkhead box protein O
(FOXOs) [14,15]. In addition to its role as a lipid phosphatase, PTEN can also exert its tumor-suppressive
function as a protein phosphatase. Through direct protein interactions, primarily in the nucleus,
PTEN is reported to directly regulate several cellular events including cell motility, chromosome stability,
the DNA damage response and cell cycle dynamics [16–19].
PTEN loss of function has been extensively characterized as a driver of prostate tumor formation
and progression using a range of experimental models [20–25]. Conditional biallelic deletion of Pten
within the basal or luminal cell compartment of the mouse prostate causes invasive prostate carcinoma
that recapitulates many features of the clinic, indicating that PTEN plays a tumor-suppressive role in the
prostate epithelium [26]. Loss of PTEN has also been shown to cooperate with other genetic alterations
including loss of the tumor suppressors (e.g., p53, RB, p27 or STAT3) and oncogenic mutations
(e.g., KRasG12D, BRaf V600E or Pik3caH1047R) in vivo, resulting in accelerated disease progression,
metastasis and/or de novo CRPC in response to castration/ADT [21,23,27–32]. Previous work in vivo
has also shown that CRPC growth is an innate property of Pten-null prostate cancer cells, irrespective of
tumor stage [33]. PTEN loss has also been linked to therapeutic resistance in the clinic, highlighting the
need for further work to identify effective treatment options for patients with PTEN deficiency [34–36].
Given the high frequency of prostate cancers that exhibit PTEN loss with augmented
PI3K–AKT–mTOR signaling, a significant amount of effort has been devoted to exploring
PI3K–AKT–mTOR-directed therapies. Until recently, clinical trials investigating these agents have had
limited success [37–42], reflecting several factors including dose-limiting toxicities and/or an inability
to suppress the pathway. However, recent trials are beginning to show efficacy, owing to an improved
molecular understanding of the complex regulatory framework within the PI3K–AKT–mTOR cascade,
the development of new therapeutic agents/strategies and novel patient stratification approaches.
Here, we review the present clinical landscape for patients with PTEN-deficient prostate cancer and
summarize the current and promising therapeutic approaches being explored to treat this aggressive
form of prostate cancer.
2. PTEN Status as a Predictive Biomarker for Prostate Cancer Treatment
The five-year survival rate for men with localized prostate cancer varies slightly depending on
geographical location but has been reported to be as high as 98%, and some patients (1–10%) can outlive
their disease without the need for invasive treatments [43,44]. Upon diagnosis, patients are stratified
for treatments according to their risk classification. Conventional risk grouping for localized disease is
based on serum PSA levels, tumor stage and Gleason score (GS), defined by the National Comprehensive
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Cancer Network (NCCN) risk groups (i.e., low risk: T1–T2a, GS≤6 and PSA <10 ng mL−1; intermediate
risk: T2b–T2c or GS 7 or PSA 10–20 ng mL−1; high risk: T3a or GS 8–10 or PSA >20 ng mL−1; high risk
for locally advanced prostate cancer: T3b–T4 or primary Gleason pattern 5 or >5 cores with GS 8–10;
and metastatic risk: N1/M1, with any T stage) [45], and recent refinements (using the International
Society of Urological Pathology (ISUP) grading system and disease volume) are currently in clinical
practice to aid treatment decisions [46]. Lately, there has been a sharp increase in the number of men
with localized disease undergoing active surveillance [47]. However, active surveillance has recently
been associated with significantly higher rates of tumor progression compared to those receiving
proactive treatments [48]. These findings suggest that a subpopulation of active surveillance patients
exists, which may benefit from more radical action. Importantly, genetic assessment of localized
prostate cancer tissue biopsies is beginning to assist risk stratification and can simultaneously provide
key molecular insight into the tumor biology to inform treatment decisions. Approved genomic tests
for predicting risk in patients with localized disease include the Prolaris cell cycle progression score,
the Decipher genomic classifier and the OncotypeDx genomic prostate score [49–52]. A string of studies
have also established that PTEN status in localized prostate cancer serves as a valuable predictive
marker for disease progression, which could improve patient selection for active surveillance and help
guide treatment decisions [53–57]. For instance, immunohistochemistry (IHC) to detect PTEN in GS7
(3 + 4) biopsies has revealed that PTEN loss is associated with increased risk of non-organ confined
disease at prostatectomy [54]. Furthermore, PTEN loss is strongly associated with advanced progression
and poor outcome [34,35]. Together these findings indicate that low-risk patients with PTEN-deficient
localized prostate cancer would benefit from radiotherapy or radical prostatectomy [2,58], although this
treatment approach remains to be investigated in the clinic.
Several assays have been developed to assess PTEN status (+/− TMPRSS2:ERG fusion) to
facilitate improved patient selection for active surveillance and/or treatment (e.g., Metamark,
Cambridge, MA, USA) [5,59,60]. However, they are not currently used routinely in clinical
practice. Common approaches to evaluate PTEN protein expression status include IHC and
immunofluorescence (IF), while fluorescence in situ hybridization (FISH) and next-generation
sequencing (NGS) assess PTEN genomic status. These methodologies have all independently identified
that PTEN loss positively correlates with worse clinicopathological features and overall outcome for
patients with prostate cancer [5,55,60–62]. Several studies have compared the accuracy of these tests,
with IHC emerging as the predominant method of choice, as it is a straightforward, inexpensive and
relatively robust assay [5,55,60]. Furthermore, analysis of PTEN protein expression by IHC has the
added advantage of detecting PTEN loss that is not caused by a genomic alteration (such as miRNA and
epigenetic silencing) and which is often missed by FISH analysis, especially in the context of PTEN loss
of heterozygosity (LOH), which is present in 15–49% and up to 50% of localized and metastatic prostate
cancers, respectively [23,63]. It has been suggested that FISH analysis should be performed when
inconclusive IHC/IF results are observed. However, a dual testing strategy could also be employed
whereby both IHC and FISH are implemented simultaneously, similarly to a new cost-effective
HER2 screening strategy developed for invasive breast cancer [2,64]. Interestingly, new artificial
intelligence-based algorithms are now being developed for automated detection and localization of
PTEN loss, which have shown high accuracy in prostate cancer IHC stained sections and could further
streamline PTEN screening [65]. Nevertheless, further work to better outline the criteria for assigning
a tumor as PTEN-deficient is needed (e.g., PTEN cellular localization, PTEN conformational state,
and the percentage of PTEN-negative prostate epithelial cells) [66–69]. In the literature, PTEN has
been shown to localize to the cytoplasm and nucleus of normal basal and luminal prostate epithelial
cells, and the surrounding stromal cells (including endothelial, smooth muscle, peripheral nerve,
fibroblast and inflammatory cells) [5,6,26,70,71], while others have additionally observed PTEN at
the membrane [5,72]. These variations are likely to reflect differences in PTEN function, but could
also relate to differences in the methodologies, such as the tissue fixation protocol and/or the antibody
binding site.
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Investigations to identify a PTEN-deficient gene signature are now underway, which could
overcome some of the limitations associated with the methodologies outlined above [73]. However,
the issue of tissue heterogeneity remains, as analysis of needle biopsies does not always represent
the whole tumor. Interestingly, liquid biopsy analysis of PTEN genomic status within circulating
tumor cells (CTCs) is also being investigated as a quick, non-invasive strategy to identify patients
with PTEN-deficient prostate cancer, with a view to inform treatment decisions [74,75]. For instance,
a blood-based CTC PTEN FISH assay is being employed in a clinical trial exploring abiraterone in
combination with PI3K/AKT inhibitors in patients with CRPC (NCT01485861) [74]. Importantly,
PTEN loss in CTCs isolated from patients with mCRPC has been shown to significantly correlate with
reduced survival in two independent studies [74,75], and several studies have revealed that PTEN loss
can influence response to current therapies [34,35,76–79]. Indeed, a recent large phase II trial in breast
cancer is already using CTC DNA analysis to match key driver mutations in CTCs, including PTEN
inactivating mutations, to select personalized therapies for patients, such as AKT-targeted therapy for
PTEN-deficient patients [80]. Thus, the routine analysis of PTEN status may not only identify patients
at risk of developing more aggressive disease, but could also be used to select more personalized
treatments (Figure 1).
High levels of intertumor and intratumor heterogeneity are a hallmark of prostate cancer,
which makes the selection of an appropriate and efficacious therapeutic approach difficult [81].
Notably, PTEN deletion is frequently observed in primary prostate tumors with high levels of
intratumor heterogeneity [82], and the heterogeneity of PTEN loss within a primary prostate tumor
has also been shown to influence clinical outcome [83]. Lotan and colleagues assessed PTEN
status by IHC in a large radical prostatectomy tissue microarray, revealing that relative to cores
with intact PTEN, PTEN homogeneous loss, but not heterogeneous loss, is significantly associated
with shorter recurrence-free survival (RFS) in multivariate models [83]. At the genomic level,
both heterozygous and homozygous deletion of PTEN significantly associate with biochemical
recurrence (based on rising PSA levels) and RFS in patients that have undergone radical prostatectomy
or brachytherapy [76]. PTEN copy number loss has also been associated with disease progression
following radiotherapy [77], which has been linked to the increased infiltration of tumor-associated
macrophages (TAMs) in PTEN-deficient tumors, which release pro-survival signals that could provide
beneficial therapeutic targets [84]. It has also been observed that in localized high risk disease,
patients with PTEN loss relapse quicker when treated with chemotherapy post-surgery compared to
those with intact PTEN [78]. However, PTEN status has been shown to have little effect on taxane-based
chemotherapy response in patients with mCRPC [36]. Finally, treatment pressure can also lead to
the acquisition of PTEN loss, as observed in PIK3CA mutant metastatic breast cancer patients that
developed resistance to the p110α-specific PI3K inhibitor apelisib (BYL719) [85]. Here, PTEN loss
is thought to reactivate the PI3K cascade via p110β to overcome p110α inhibition. Taken together,
these findings further highlight the predictive value of PTEN status in prostate cancer and emphasize
the need for future work to identify beneficial stratification strategies for PTEN-deficient prostate cancer
in order to better inform clinical trial design and improve patient care. To this end, improving our
molecular understanding of the functional consequence of PTEN loss during prostate cancer growth
and in response to therapeutic intervention is paramount.
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1. Tailoring treatments f r local and me astatic prostate cancer based on PTEN status.
Image shows hypothetical guidelines f r diag osing and treating prostate cancer following PTEN
screeni . Following n abnormal PSA and/or digital rect l examination (DRE), men with suspected
prostate cancer would be advised by a sp cialist regarding the potential risks and benefits of the
various treatment options before being iagn sed following current NICE guidelines. For suspect
localized or locally advanced prostate cancer, multiparametric magnetic resonance imaging (mpMRI)
scans sho ld be used where available as first-line investigation, with patients sc ring 3 or more
on the Likert scale offered a mpMRI-influenced prostate biopsy. Alongside normal assessment of
PSA, the Gleason score and clinical stage, additional analysis of PTEN status by IHC and/or FISH
should help determine appropriate risk category by multidisciplinary teams. Those with low- or
intermediate-risk localized disease with normal PTEN expression can be offered a choice of active
surveillance, radical prostatectomy or radiotherapy. Patients with intermediate localized or high locally
advanced disease with PTEN loss should not be offered active surveillance and may be treated with
docetaxel if high risk with no significant comorbidities. ADT therapy plus PI3K–AKT–mTOR-targeted
therapies may be beneficial for high-risk patients where PTEN has been lost but this has not been
tested clinically. If metastatic disease is detected in patients who have progressed from locally
advanced disease, PTEN status should be re-assessed by analysis of CTCs if previous biopsy analysis
detected normal PTEN status. Newly diagnosed metastatic disease or for those who have not received
a mpMRI biopsy should also have CTCs assessed to determine PTEN status. Patients with mHSPC and
normal PTEN expression should proceed with ADT alongside second-generation androgen/Androgen
Receptor (AR)-targeting therapies such as abiraterone or enzalutamide, but if PTEN has been lost,
docetaxel should be used as a first-line treatment alongside ADT as PTEN loss has been shown to
promote resistance to next-generation hormonal therapies. The use of AR-targeted therapies may
be efficacious alongside PI3K–AKT–mTOR inhibition, although this needs to be extensively tested
clinically. As mHSPC progresses to mCRPC, patients should be retested for loss of PTEN expression in
CTCs if they were previously diagnosed with PTEN-positive disease and then proceed to taxane-based
treatments if they have previously received abiraterone and/or enzalutamide and are still presenting
PTEN-positive disease. For newly presenting mCRPC where PTEN is lost, taxane-based therapies
should also be used upfront before experimental PI3K–AKT–mTOR inhibitors are used alongside
abiraterone or enzalutamide. ADT, androgen-deprivation therapy; CT scan, computerized tomography
scan; DRE, digital rectal exam; mpMRI, multiparametric magnetic resonance imaging; mCRPC,
metastatic castrate-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer;
PI3K/AKT/mTORi, PI3K/AKT/mTOR inhibitor; PSA, prostate-specific antigen.
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The standard of care for patients that present with mHSPC is shifting towards earlier treatment
of ADT in combination with abiraterone, enzalutamide or docetaxel, with several landmark clinical
studies highlighting the significant clinical benefits of these combined therapeutic strategies compared
to ADT alone [86–91]. Despite these promising results, the challenge remains to further stratify patients
towards drug combinations that are likely to offer the most benefit. PTEN loss could become a useful
biomarker in this setting, as patients whose prostate cancer is maintained through ADT are more
likely to progress quickly to lethal mCRPC if PTEN has been lost [35,92,93]. Furthermore, loss of
PTEN has been shown to downregulate AR activity and can promote resistance to next-generation
hormonal therapies such as abiraterone. Therefore, PTEN-deficient patients with advanced prostate
cancer may benefit more from taxane-based therapies [33,34,36]. In the mHSPC setting upfront ADT
alongside docetaxel could be the best approach to offer long-lasting responses following PTEN loss,
while similarly in mCRPC, taxane-based therapies are likely to be the most effective upfront therapy
compared to second-generation AR-targeting treatments (Figure 1). New data are now beginning to
suggest that second-generation hormonal therapies may be more effective in PTEN-deficient mCRPC
when used alongside PI3K–AKT–mTOR inhibition (discussed below). However, these approaches will
require further clinical evaluation before being introduced as a standard treatment option. Whether the
success of these new combinations may also translate into the mHSPC setting remains to be established.
However, a new clinical trial to explore this is now actively recruiting (NCT04493853).
3. Targeting PTEN-Deficient Prostate Cancer
Given the high frequency of PTEN loss in prostate cancer, therapeutic strategies that exploit the
functional loss of PTEN may prove to be efficacious against PTEN-deficient prostate cancer. Below,
we discuss the recent advances in the development of agents that can directly restore PTEN function
and the therapeutic approaches to inhibit the PI3K–AKT–mTOR signaling network.
3.1. Direct Restoration of PTEN Function
In theory, perhaps the simplest approach to overcome PTEN-deficient prostate cancer is to
restore PTEN function. Multiple lines of evidence in the literature have indicated that PTEN
plays a haploinsufficient tumor-suppressive role. Transgenic mouse models have shown that
PTEN haploinsufficiency or heterozygosity in mouse prostate epithelium can cause prostate lesions,
whereas homozygous PTEN deletion causes prostate carcinoma [20,23,94]. Moreover, PTEN loss has
been shown to cooperate with other oncogenic events to accelerate prostate cancer progression in vivo
in a dose-dependent manner, and heterozygous loss of PTEN has been shown to accelerate prostate
cancer progression in some clinical datasets [22,76,79,95–97]. These findings underpin the notion that
artificially increasing the ‘functional dose’ of PTEN, even slightly, could elicit a significant reduction
tumor burden and/or the rate of caner progression by restoring PTEN tumor-suppressive functions,
thus presenting an attractive therapeutic approach. Accordingly, several novel treatment strategies are
being developed to directly restore PTEN function (Figure 2), as outlined below.
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3.1.1. Direct Delivery of PTEN and PTEN-Long
To increase the functional dose of PTEN in PTEN-deficient prostate cancer, therapeutic approaches
designed to deliver PTEN directly into prostate cancer cells are currently being studied. Historically,
the systemic delivery of macromolecules such as PTEN has been challenging, largely due to issues
such as high renal clearance, rapid protein degradation and poor membrane permeability limiting
intracellular uptake [98]. However, the recent, rapid advancement of protein modification techniques
and novel delivery systems (e.g., micro and nanoparticle encapsulation) has made the delivery of
PTEN into tumor cells feasible [98]. Significantly, intracellular nanoparticle assisted delivery of
recombinant PTEN protein has been successfully used in PTEN-deficient prostate cancer cell lines
in vitro to reduce cell viability, and PTEN has been shown to accumulate at PC-3 xenografts in vivo
using a nanoparticle delivery system [99,100]. A similar approach has also been used to deliver PTEN
mRNA, yielding promising results in PC-3 tumor models in vivo, reducing both primary and metastatic
tumor growth through suppression of the PI3K–AKT signaling pathway [101]. These findings suggest
that this therapeutic approach may also prove to be efficacious in patients. Interestingly, in vitro
studies have shown that PTEN can also be secreted via exosomes, which can then be taken up by
surrounding recipient cells to reduce AKT activity and cell proliferation [102]. This system could be
exploited therapeutically, and encouragingly exosome-based delivery of the C-terminus region of
PTEN (that stabilizes PTEN) has shown anti-tumor effects in breast cancer models, both in vitro and
in vivo [103]. Consequently, this approach could transpire to be particularly beneficial in patients with
PTEN mutations in this hotspot region.
The discovery of PTEN-Long has added an additional therapeutic opportunity to reinstate the
tumor-suppressive function of PTEN to treat PTEN-deficient cancers. PTEN-Long is a translational
variant of PTEN that includes an additional 173 amino acids at its N-terminus (N-173), which allows it
to be secreted and taken up by surrounding cells to suppress PI3K–AKT–mTOR signaling and induce
tumor cell death [104]. Although little work has been performed to harness the therapeutic potential of
PTEN-Long in prostate cancer, purified PTEN-Long (but not purified PTEN) has been shown to inhibit
tumor proliferation and induce tumor regression in a clear cell renal cell carcinoma xenograft model
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in vivo [105]. Furthermore, an altered version of PTEN-Long engineered to improve secretion efficiency
has been investigated in a cell-mediated protein delivery system, which showed biological activity
in vitro against neighboring glioblastoma cell lines [106]. Taken together, these preclinical studies
highlight the therapeutic potential of PTEN-Long delivery to treat PTEN-deficient epithelial cancers.
However, further work is needed to gain insight into the most beneficial approach for PTEN-deficient
prostate cancer (e.g., PTEN vs. PTEN-Long delivery). To this end, increased molecular characterization
of the mode of action of PTEN-Long is needed to determine tissue specificity and to establish the
existence/functional importance of the PTEN-independent functions of PTEN-Long, especially given
that the PTEN-Long N-173 tail is considered to harbor multiple protein-binding sites [107].
3.1.2. Restoring PTEN Function by Targeting PTEN-Negative Regulators
Restoration of PTEN expression by overcoming its transcriptional and post-transcriptional
repression is also being investigated as an avenue for therapeutic intervention to increase PTEN
activity (Figure 2). Although PTEN is frequently lost through genomic alterations, post-transcriptional
acetylation, ubiquitination and phosphorylation of PTEN have also been shown to impair PTEN
stabilization, localization and/or phosphatase activity, while a number of regulatory proteins have also
been shown to interact with PTEN at various binding sites to mediate PTEN activity (reviewed in [108]).
For example, the cytosolic mannosidase α-mannosidase 2C1 (MAN2C1) has been shown to interact
with and negatively regulate the lipid phosphatase activity of endogenous PTEN, and MAN2C1
overexpression stimulates AKT signaling and promotes prostate tumorigenesis in PTEN-positive
DU145 prostate cancer xenografts [109]. Furthermore, PTEN-positive prostate cancers frequently
overexpress MAN2C1, and MAN2C1 expression in prostate cancer significantly correlates with reduced
recurrence-free survival [109]. Although limited research has explored the therapeutic benefit of
targeting MAN2C1, silencing of MAN2C1 by siRNA has been shown to induce apoptosis in esophageal
carcinoma cells [110], while its suppression in nasopharyngeal carcinoma cells has been demonstrated
to inhibit tumor formation and metastasis in vivo [111]. These findings illustrate the therapeutic
benefit of targeting proteins that negatively regulate PTEN post-translation, and corroborate the need
for future work to comprehensively investigate the therapeutic benefit of targeting PTEN-negative
regulators in prostate cancer with inactive PTEN, and to establish their true predictive value.
3.1.3. miRNA Targeting to Restore PTEN Transcriptional Activity
PTEN expression is also regulated post-transcriptionally by non-coding oncogenic microRNAs
(miRNAs) known as oncomiRs. To date, oncomiRs such as miR-17, miR-20a, miR-21, miR-22,
miR-25, miR-93, miR-106a/b, miR-153, miR-498 and miR-4534 have each demonstrated the ability
to downregulate PTEN expression in prostate cancer cells, thus presenting potential therapeutic
targets [112–120]. Perhaps the most promising preclinical candidate for restoring PTEN function
is miR-21, which has been successfully silenced using antisense anti-miR oligonucleotides (AMOs)
and locked nucleic acid (LNA) conjugated to lipid nanocapsules in other cancer types [121,122].
Additional methods to inhibit oncomiRs include small-molecule inhibitors of miRNAs (SMIRs),
anti-miRs, antagomiRs and bacterial-based TargomiRs (Figure 2) [123,124]. With clinical trials
investigating LNA anti-miRs, TargomiRs and liposomal packaged miRNAs designed to target various
oncomiRs in solid tumors beginning to recruit, and initial reports showing relatively good safety
profiles, this approach could be readily applied to multiple cancer types with PTEN deficiency in the
near future, including prostate cancer [123,125–127]. Nevertheless, the mechanism through which
PTEN has been lost and off-target effects remain two important considerations for future clinical trials
investigating the targeting of oncomiRs to treat PTEN-deficient prostate cancers [128].
Lastly, although epigenetic silencing of PTEN in prostate cancer is uncommon,
demethylating agents able to restore PTEN expression may also offer a beneficial therapeutic approach
for patients with PTEN silencing [129]. For instance, in a non-small-cell lung carcinoma cell line the
demethylating agent decitabine (5-aza-2′-deoxycytidine) was able to increase PTEN mRNA levels,
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while knockdown of the DNA methyltransferase enzyme DNA (cytosine-5)-methyltransferase 3A
(DNMT3A) in a hepatocellular carcinoma cell line resulted in demethylation of the PTEN promoter and
upregulation of PTEN mRNA expression [130,131]. Although there is a lack of evidence for the direct
restoration of PTEN through manufactured demethylating agents in PTEN-silenced prostate cancer,
the naturally occurring dietary compound resveratrol has been shown to promote PTEN acetylation
and reactivation by inhibiting a an interaction between the metastasis-associated protein 1 (MTA1)
and histone deacetylase (HDAC) complex in prostate cancer cells [132].
3.1.4. CRISPR/Cas9-Guided Transcriptional Activation of PTEN
The use of genome editing technology to directly reactivate PTEN is a relatively new approach
being investigated to treat PTEN-deficient cancer that is not caused by a genetic alteration in PTEN,
although this approach may only be applicable for up to 10% of PTEN-deficient prostate cancers
in which PTEN transcription is suppressed by negative transcriptional regulators of PTEN or via
promoter methylation [2]. Recent work has shown that CRISPR/dCas9 gene editing can be been used
to activate PTEN transcription in breast cancer and melanoma cell lines that harbor wild-type PTEN
alleles but have low PTEN expression in vitro [133]. Here, a kinase dead Cas9 (dCas9) fused to a VPR
(VP64, p65, and Rta transactivator) effector domain (termed dCas9-VPR activation system) was used to
target the proximal promoter region of PTEN, resulting in increased PTEN mRNA levels and PTEN
protein expression, which suppressed downstream AKT/mTOR signaling [133]. Importantly, no mRNA
expression changes were observed in previously identified potential off-target genes in this setting.
However, future work focusing on the delivery of these constructs in vivo will be vital for advancing
their clinical utility (discussed below). In addition, CRISPR/Cas9 technology has also been employed
to alter the start codon of PTEN-Long in HEK293 cells, resulting in a significant increase in PTEN-Long
expression and secretion [134]. Remarkably, the transfer of conditioned media from these cells to
cultured PTEN-null glioblastoma U87 cells resulted in the uptake of PTEN-Long, which led to reduced
AKT signaling and cell proliferation [134]. Although transcriptional activation of PTEN is yet to be
achieved in vivo, CRISPR/Cas9-mediated repression of PTEN in mouse models has demonstrated the
ability of this system to target PTEN in vivo to rapidly induce PTEN-deficient murine liver disease and
mammary tumors [135–137]. Future studies to determine whether CRISPR/Cas9-guided therapeutic
approaches in patients with low PTEN expression that carry a monoallelic genetic aberration in PTEN
will be of great interest to the field, possibly extending the application of this therapeutic strategy to
a larger population of patients.
Notably, Cas9-nickases that induce DNA single-strand breaks offer a potential tool to correct
somatic PTEN mutations, as they can be modified to introduce single nucleotide base changes, and this
approach has previously been shown to correct TP53 mutations in breast cancer cell lines [138].
Genome editing has been used in a number of clinical trials for various pathological conditions.
However, the majority of these genetic modifications have been undertaken ex vivo using patient or
donor cells, which are then engrafted into the patient [139]. To target PTEN genetic alterations in
patients with prostate cancer, an in vivo approach is needed. However, several non-trivial hurdles
will need to be overcome first, including the efficiency of delivery, immunogenicity and off-target
effects [139,140]. To date, in vivo approaches have focused on readily accessible tissues, with direct
targeting of the prostate likely to be a significant challenge. Both viral and aptamer-liposomal systems
have been used to deliver CRISPR guides specifically to the prostate epithelium in mice, with the latter
showing promising anti-tumor efficacy and a limited immune response, suggesting that this could be
a viable option in the future [141,142].
In conclusion, a wide range of therapeutic approaches to restore PTEN activity are in development,
which target multiple PTEN-negative regulation events. As this field continues to rapidly grow and
delivery mechanisms significantly improve, these types of approaches could become much more
feasible, opening the door to an exciting and potentially highly effective method of restoring functional
PTEN in PTEN-deficient prostate cancer. Advantageously, this approach could also overcome the
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complex mechanisms of resistance that have hindered other therapeutic strategies targeting the
PI3K–AKT–mTOR cascade (discussed below). However, the co-occurrence of other genetic drivers of
the PI3K pathway with PTEN loss, and the cause of PTEN loss would need to be carefully considered
when selecting patients for treatment. Further work to establish an in-depth understanding of the
molecular mechanism by which PTEN is regulated would provide important insights into how
PTEN-negative regulation can be most effectively targeted, and studies to identify which patients
are most likely to benefit from restoring PTEN activity by targeting specific PTEN regulation events
are warranted.
3.2. PI3K Inhibition
Oncogenic PI3K signaling frequently occurs in prostate cancer, and is invariably activated in
metastatic disease [21,143–145]. The PI3Ks are a family of intracellular signal transduction enzymes
that can be separated into 3 structurally and functionally defined classes (Class I, that is subdivided
into Class 1A and Class 1B, Class II and Class III). Here, we focus on Class1A PI3Ks, which have been
shown to contribute to prostate tumor formation and progression [146,147] (for more information on
Class II and Class III PI3Ks refer to [144,148]). Class IA PI3Ks function as heterodimers comprised
of a catalytic isoform (p110α, p110β, and p110δ) and a regulatory subunit (p85α, p85β, p55α,
p55γ or p50α) that catalyze the convsion of PIP2 to PIP3 upon recruitment to the cytoplasmic
domain following the activation of upstream receptors (e.g., receptor tyrosine kinases, RTKs,
G-protein coupled receptors, GPCRs) and small GTPases [147]. PTEN is a master regulator of the
PI3K cascade, that antagonizes PI3K catalytic activity and therefore restricts PIP3-mediated secondary
messenger signaling and downstream processes [149]. PIP3 recruits several effector proteins that bind
via a pleckstrin homology domain (PH domain), including AKT and phosphoinositide-dependent
kinase-1 (PDK1). Upon recruitment, AKT is subsequently phosphorylated at Thr308 by PDK1,
triggering a wave of AKT-mediated phosphorylation events that mediate cell survival, proliferation,
glucose metabolism and ribosomal biogenesis through multiple downstream effector pathways (e.g.,
mTORC1 signaling) [150]. Further phosphorylation of AKT at Ser473 by mTORC2 results in AKT
hyperactivation [150,151].
In prostate cancer, activation of the PI3K–AKT–mTOR cascade occurs through multiple
mechanisms (reviewed in [144]). Although PTEN loss is the most frequent cause, a range of distinct
genetic alterations can also cause oncogenic signaling of this pathway. These include activating
mutations in AKT and PIK3CA/PIK3CB, which encode the p110α/p110β catalytic PI3K subunits,
respectively [152,153]. Interestingly, genetic alterations in PIK3CA have a strong tendency to coexist
with PTEN deep deletion/mutation in patients with prostate cancer, and we have previously shown
in mice that Pten homozygous deletion and an activating mutation in Pik3ca at H1047R synergize
to promote prostate cancer progression and de novo CRPC [21]. The high frequency of deregulated
PI3K–AKT–mTOR signaling has led to the development of several small-molecule inhibitors designed
to target individual p110 PI3K catalytic isoforms as well as pan-PI3K inhibitors, AKT inhibitors,
mTOR inhibitors, and a number of dual action PI3K/mTOR inhibitors (Figure 3) [154].
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lthough early clinical trials involving these inhibitors were terminated due to substantial toxicity
issues and a lack of on-target efficacy, several recent trials are beginning to show promising results in
a variety of cancer types, including prostate cancer [154]. I itial studies with the non-specific PI3K
antagonist LY294002 suggested that PI3K inhibition could inhibit invasion [155], angiogenesis [156]
and sensitize prostate cancer cells to radiation therapy [157]. However, this agent has not entered clinical
evaluation due to severe toxicity observed in mice [158]. The pan-PI3K inhibitor buparlisib (BKM120) is,
however, well tolerated in mice, and in vivo preclinical studies in a variety of cancer types have reported
anti-tumor efficacy associated with reduced AKT activity in response to buparlisib treatment, including
prostate cancer models [21,159–162]. A phase 1 study in men with high-risk, localized prostate
cancer using buparlisib pre-prostatectomy (NCT01695473) confirmed that buparlisib can inhibit AKT
activity, yet no change in cell death or proliferation was observed [163]. The pan-PI3K inhibitors
copanlisib (BAY 80–69460) and pilaralisib (XL-147) have also been shown to decrease PI3K activity
in vitro, with the latter showing a significantly higher potency in PTEN-deficient prostate cancer cell
lines [164,165]. Interestingly, one clinical study is currently recruiting to test the efficacy of copanlisib
in combination with the PARP inhibitor rucaparib in mCRPC (NCT04253262). However, to our
knowledge, pilaralisib is yet to be investigated clinically to treat prostate cancer. Dactolisib (BEZ235),
a dual PI3K/mTORC1/2 inhibitor has also shown good anti-tumor activity in various preclinical models,
including PTEN-null prostate cell lines [159,166]. However, clinical testing in several cancer types,
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including one study in mCRPC in combination with abiraterone (NCT01717898), has been terminated
early owing to dose-limiting toxicities [38,167].
A range of highly potent PI3K catalytic isoform-specific inhibitors have also been developed,
providing an opportunity to reduce the therapeutic dose administered and limit toxicity [154].
While PIK3CA mutant prostate cancers have been shown to respond to p110α isoform-specific
inhibition, previous work by us and others has shown that targeting p110α alone in prostate cancers
with PTEN loss is not efficacious, owing to p110β dependency [21,144,168,169]. Although acquisition
of PTEN genetic alterations in response to the p110α inhibitor alpelisib (BYL719) have been shown
to drive resistance in metastatic breast cancer patients [85], indicating that similar mechanisms of
resistance may emerge in PTEN-deficient prostate cancer, p110α inhibition may still prove to be
efficacious against prostate cancers that are both PTEN-deficient and carrying an activating PIK3CA
mutation. Whether combining p110α- and p110β-specific inhibitors is more efficacious and/or less
toxic than a pan-PI3K inhibitor is also yet to be explored clinically.
The reliance of PTEN-deficient prostate cancers on p110β activity underpins the rationale for
clinical trials exploring the efficacy of p110β-targeted inhibition. The p110β-selective inhibitor
GSK2636771 (which also selectively targets p110δ, albeit less potent) has shown promise in mCRPC in
a first-in-human trial (NCT01458067) [170]. In addition, GSK2636771 combined with enzalutamide in
PTEN-deficient mCRPC patients is reported to be well tolerated, with 1/13 evaluable patients showing
a partial radiological response and, encouragingly, another two patients displayed maximum PSA
reductions (>50%) (NCT02215096) [171]. Co-targeting p110β and p110δ in mCRPC is also being
explored using the dual p110β/p110δ PI3K inhibitor AZD8186 +/− abiraterone (with prednisone),
plus an expansion phase with PTEN-deficient/mutated or PIK3CB-mutated mCRPC (NCT01884285).
A phase I trial is also studying the efficacy of AZD8186 in combination with docetaxel in PTEN or
PIK3CB mutant mCRPC patients (NCT03218826). Preclinically, two additional p110β-specific inhibitors
KIN-193 (AZD6482) and SAR260301 have also shown efficacy in various murine PTEN-deficient
cancer models in vivo [172,173], further supporting the therapeutic strategy of targeting p110β in
cancers with PTEN loss. Nevertheless, clinical evaluation has not progressed beyond phase 1 for
either drug. SAR260301 was unable reduce AKT signaling due to rapid clearance (determined by an
ex vivo platelet p-AKT-inhibition assay) (NCT01673737) [174], and AZD6482 has not been followed
up clinically in an anti-tumor setting since its initial phase 1 safety and tolerability study performed
>10 years ago (NCT00688714). The p110β isoform-specific PI3K inhibitor TGX-221 and its analogue
BL140 have also both shown efficacy in preclinical models of prostate cancer with PTEN loss [175–179],
and BL140 is also reported to overcome resistance to enzalutamide in vitro [179]. Controversially,
however, previous work by us indicates that TGX-221 treatment alone in a Pten-deficient prostate
cancer transgenic mouse model is not sufficient to significantly reduce tumor burden, although tumor
regression was observed when TGX-221 was combined with the p110α isoform-specific PI3K inhibitor
A66 [21], indicating that p110β inhibition may shift dependency to p110α in this setting [21,168].
Consequently, further work is needed to improve our understanding of the compensatory mechanisms
between p110 isoforms in response to p110 isoform-specific blockade to improve future clinical trial
design, and these findings provide additional support for future studies exploring p110α and p110β
isoform-specific inhibitor combination therapy in patients with PTEN loss.
Several mechanisms of resistance to PI3K inhibitors have been identified, including hormone
receptor dependency, activation of downstream kinases, gene expression deregulation via aberrant
transcription factor signaling and increased reliance on alternative p110 isoforms which can each
help drive cell growth [180]. To overcome PI3K inhibitor resistance, a number of combination
therapy approaches have been explored. Previous work has revealed that the dual PI3K/mTOR
inhibitor dactolisib (BEZ235) promotes AR signaling in a HER2/3 dependent manner in PTEN-deficient
prostate cancer models, while AR-targeted therapy augments AKT signaling [181]. This important
study identified a reciprocal feedback loop exists between the PI3K and AR signaling pathways,
and that relative to monotherapy, combined dactolisib and enzalutamide (MDV3100) treatment shows
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superior efficacy in both a Pten-deficient murine prostate cancer model and human prostate cancer
xenografts [181]. These data provide a clear justification for combining PI3K pathway (or HER2 kinase)
inhibition with anti-androgen/AR-directed therapy in the clinic, and multiple clinical trials are
now exploring PI3K and AR pathway co-inhibition in mCRPC [37,182,183]. However, a phase 1b
study testing dactolisib or buparlisib in combination with abiraterone was terminated early due to
dose-limiting toxicity including hyperglycemia, a lack clinical efficacy and a poor pharmacokinetic
profile [183], and a phase 2 study combining buparlisib and enzalutamide in mCRPC patients saw
no significant PSA reductions and no radiographic responses in the 30 men tested [37]. Nonetheless,
combining the dual PI3K/mTOR and DNA-dependent protein kinase (DNA-PK) inhibitor Samotolisib
(LY3023414) with enzalutamide to treat mCRPC that has progressed on abiraterone has shown
early promise, and a manageable safety profile (NCT02407054) [182]. The median radiographic
progression-free survival (rPFS) was 7.5 months compared to 5.3 in those treated with enzalutamide
alone (HR ratio = 0.68), and patients with androgen receptor variant 7 (AR-V7)-negative disease
showed a remarkable increased in rPFS (13.2 months, HR ratio = 0.52) [145]. Upcoming results from
a trial exploring the dual PI3K/mTOR kinase inhibitor apitolisib (GDC-0980) in combination with
abiraterone (NCT01485861) are also expected to provide further insight into the therapeutic benefit of
this co-targeted approach. The efficacy of the dual PI3K/HDAC inhibitor fimepinostat (CUDC-907)
is also currently being assessed clinically in various solid tumor types and although this does not
currently include patients with prostate cancer, fimepinostat is reported to reduce tumor growth in the
PTEN-deficient LuCaP 35CR PDX CRPC model [184,185].
While p110δ signaling has been predominantly shown to play an oncogenic role in hematological
malignancies [148], mRNA levels of PIK3CD (that encodes p110δ) are reported to increase in
prostate carcinoma compared with normal prostate, and PI3K pathway activation in PTEN-deficient
prostate cancer cells has been shown to involve both p110β and p110δ PI3K signaling [186,187].
These data suggest that targeting the p110δ catalytic PI3K isoform may be efficacious in prostate
cancer in combination with the inhibition of other p110 catalytic PI3K isoforms. In addition to the
p110β/δ-selective inhibitors discussed above, the selective p110α/β/δ PI3K inhibitor BAY1082439
is reported to inhibit tumor growth in a bi-allelic Pten-deficient prostate cancer transgenic mouse
model, and can prevent invasive progression and reduce epithelial-to-mesenchymal transition (EMT)
in the Pten-deficient, KRas+/G12D mutant mouse model of metastatic prostate cancer [188]. Notably,
BAY1082439 was shown to target both prostate tumor cells intrinsically and the surrounding tumor
microenvironment, as targeting p110δ also blocks B-cell infiltration and lymphotoxin release in the
tumor microenvironment that can promote CRPC growth [188]. A phase 1 dose-escalation study to
assess the safety and tolerability of BAY1082439 in patients with advanced solid malignancies has now
been completed (NCT01728311). However, no results from this study have been disclosed to date.
3.3. AKT Inhibition
In the absence of PTEN, PI3K activity results in the uncontrolled production of the phospholipid
second messenger PIP3, resulting in the activation of several downstream effector proteins such as the
serum/glucocorticoid-regulated kinases (SGKs), protein kinase C (PKC), Rho family GTPases and the
well-characterized AKT signaling cascades to mediate cell growth, proliferation and migration [189–
191]. AKT is a serine/threonine protein kinase, of which three structurally similar isoforms exist
(AKT1, AKT2 and AKT3) that are differentially expressed across tissue compartments, with AKT1
being the most abundantly expressed across most tissues [192]. Activating mutations in AKT1–3
are relatively rare in prostate cancer, while gene amplification has been observed in up to 4.5%
(AKT1), 2% (AKT2), and 4.7% (AKT3) of prostate cancer cases, respectively [144]. The importance
of each AKT isoform in PTEN-deficient prostate cancer remains unclear, with some preclinical data
suggesting a higher dependency on AKT2 compared to AKT1 [193], yet only deletion of Akt1 and
not Akt2 has been shown to suppress prostate neoplasia in a Pten+/− transgenic mouse [194,195].
Interestingly, overexpression of AKT3 in PTEN-null PC-3 mCRPC cells can promote proliferation
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and tumor growth in vivo [196], whereas systemic deletion of Akt3 has been shown to trigger
neurological conditions, including depressive and anxiety-like behaviors in mice [197]. In contrast,
systemic deletion of Akt1 or Akt2 in mice increases mortality, due to significant disruptions in
circulating glucose and insulin levels, resulting in hyperglycemia, which is notably a known adverse
effect of pan-AKT inhibitors in the clinic [198]. However, manageable clinical safety profiles are now
being established for pan-AKT inhibitors administered alone and in combination with established
taxane-based or androgen/AR-targeted therapies, with patient responses linked to dysregulated
PTEN/PI3K signaling in several solid tumors (including prostate cancer) [199–205]. Preclinical studies
have also supported the stratification of PTEN-deficient prostate cancer patients for AKT inhibitor
treatment [206–210], yet activation of potential therapeutic resistance pathways has been observed
(discussed below, [180,207,211,212]). These findings underscore the need to further explore the
molecular mechanisms underlying AKT-inhibitor resistance to aid the discovery and development of
novel therapeutic strategies that can improve patient outcome, including combination therapies.
Pan-AKT inhibitors that are currently in clinical testing include capivasertib (AZD5363),
MK-2206 and ipatasertib (GDC-0068), with preclinical data showing increased sensitivity in various
PTEN-deficient cancer lines and xenograft models (including prostate cancer) [208–210]. Moreover,
capivasertib monotherapy in PTEN-deficient intact or castrated prostate cancer mouse models has
shown strong anti-tumor effects, and improves survival in an aggressive prostate cancer model driven
by PTEN/p53 loss [207]. Similarly, MK-2206 was shown to significantly reduce tumor growth in
a PTEN-deficient prostate cancer model. However, mTOR activity was not suppressed suggesting that
mTOR signaling is regulated independently of AKT in this setting [206]. Dose-dependent responses
in PTEN-null and PTEN-low prostate cancer lines have also been observed following ipatasertib
treatment, further supporting the finding that AKT inhibition can inhibit PTEN-deficient prostate
cancer growth [210].
Clinical evaluation in mCRPC patients has confirmed that capivasertib is tolerable in combination
with docetaxel and enzalutamide, with the latter combination showing clinical responses in patients
with PTEN loss [199,200]. Follow-up phase II studies are currently ongoing using these combinations,
which could provide further insight into how these therapies could be tailored to benefit patients
(NCT04087174 and NCT02525068). Ipatasertib combined with abiraterone is also reported to have
a good tolerability profile in mCRPC patients [213], and another active study will test the safety
and therapeutic benefit of ipatasertib in combination with docetaxel (NCT04404140). Interestingly,
a phase II study combining ipatasertib and abiraterone has reported reduced rPFS in mCRPC patients,
with a greater response observed in tumors with PTEN loss (NCT01485861) [214]. Early data presented
at the European Society of Medical Oncology (ESMO) 2020 virtual annual meeting from the ongoing
phase III IPATential150 study (NCT03072238) showed similar promising responses in PTEN-deficient
prostate cancer using the same treatment combination (with the addition of prednisone to the abiraterone
arm). Another ongoing clinical trial is also testing MK-2206 in combination with bicalutamide in
high-risk prostate cancer patients post-surgery, radiotherapy or cryoablation (NCT01251861), and two
structurally similar AKT inhibitors, uprosertib (GSK2141795) and afuresertib (GSK2110183), are also
being tested clinically. To date, uprosertib has shown partial responses in two patients with either
a PIK3CA mutation or PTEN loss (by IHC) in a phase I study in solid tumors [215], while afuresertib is
currently under investigation in mCRPC patients (NCT04060394).
Taken together, the early clinical data from studies exploring AKT inhibitors in prostate cancer
is promising, particularly in combination with androgen/AR blockade. Furthermore, PTEN loss is
emerging as a key biomarker for patient response. Nevertheless, despite clinically manageable safety
profiles being reported, toxic side effects (including hyperglycemia and diarrhea) associated with
PI3K/AKT inhibition remain a concern for patients and clinicians, and new approaches to overcome
this issue are in demand. Interestingly, the use of metformin in combination with AKT inhibition has
been suggested to decrease insulin levels and limit these adverse side effects [192,216], while similar
results have been observed with PI3K inhibitors used alongside a ketogenic diet [217].
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3.4. mTOR Inhibition
The mTORC1 and mTORC2 signaling pathways play an important role in mediating PI3K/AKT
signaling by regulating AKT activity directly (mTORC2) and indirectly (mTORC1) [218]. A number of
feedback loops also exist between the mTORC1 and mTORC2 pathways enabling cross-regulation [218].
Structurally, both complexes center around the protein kinase mTOR, mammalian lethal with SEC13
protein 8 (mLST8) and DEP domain-containing protein 6 (DEPTOR). However, they differ in additional
components [219]. For example, the mTORC1 complex includes the regulatory-associated protein of
mTOR (RAPTOR) and the proline-rich AKT substrate of 40 kD (PRAS40), while mTORC2 contains
the rapamycin-insensitive companion of mTOR (RICTOR) and mammalian stress-activated protein
kinase-interacting protein 1 (MAPKAP1/mSIN1) [219]. These structural differences allow each complex
to perform distinct functions, which ultimately promote AKT signaling and facilitate tumor growth
and progression. With the exception of DEPTOR gene amplification, genetic alterations to mTORC1/2
components are relatively infrequent in prostate cancer [144]. However, both complexes are commonly
activated via upstream activation of the pathway [144]. Paradoxically, amplification of DEPTOR has
been shown to correlate with worse progression-free survival [144], while a reduction in DEPTOR
protein and mRNA transcript levels has also been implicated with prostate cancer progression [220].
Furthermore, systemic deletion of Deptor in a Pten+/− transgenic mouse was shown to promote prostate
tumorigenesis accompanied with increased mTORC1/2 signaling, suggesting that the restoration of
DEPTOR could be a beneficial therapeutic approach for PTEN-deficient prostate cancer [220].
Deciphering the role of mTORC1 in PTEN-deficient prostate cancer has been largely assessed
through a series of studies using sirolimus (rapamycin) and its analogues (rapalogs), which potently
inhibit mTORC1, with minimal effect on mTORC2, unless under prolonged exposure [221,222].
Short-term treatment with rapamycin in Pten+/− mice on a C57BL/6 background can suppress
mTORC1 activity and inhibit the formation of prostate tumorigenesis, suggesting that tumor growth
is mTOR dependent in this setting [223], and this anti-tumor effect is further supported by several
independent studies in other Pten-deficient cancer models treated with rapamycin analogues [224–228].
Conditional co-deletion of Pten and tuberous sclerosis 1 (Tsc1), which negatively regulates mTORC1
activity, has also been shown to promote tumor growth in a liver cancer mouse model [229]. Further work
has also indicated that inactivation of tuberous sclerosis 2 (TSC2) is required for PTEN-dependent
prostate tumor growth [230]. However, two separate studies have rebuked this finding by showing that
there is no cooperation between Tsc2/Pten co-deletion during prostate tumorigenesis in mice [223,231].
Hence, the functional role and therapeutic benefit of targeting TSC1/TSC2 in PTEN-deficient prostate
cancer remains unclear [232].
Interestingly, mTORC2, and more specifically RICTOR, is reported to be required for
PTEN-deficient prostate tumorigenesis in mice [233], suggesting that targeting RICTOR/mTORC2
may be efficacious against PTEN-deficient prostate cancer in the clinic [233]. Dual mTORC1/2
inhibitors have also been developed that may overcome mTORC1 therapeutic resistance via oncogenic
mTORC2 signaling [234,235]. Encouragingly, the dual mTORC1/2 inhibitor AZD8055 (discontinued)
can significantly inhibit cell growth in rapamycin-resistant PTEN-deficient prostate cancer cells
in vitro [236], and the dual mTORC1/2 inhibitors vistusertib (AZD2014), RapaLink-1 and sapanisertib
(INK-128, MLN0128) are reported to significantly decrease tumor growth in PTEN-deficient prostate
cancers in patient-derived xenograft and/or transgenic mouse models, further adding to the appeal
of targeting mTORC1/2 clinically [237–239]. Notably, in patients receiving a tolerable 2 week course
of vistusertib treatment prior to radical prostatectomy is reported to correlate with mTORC1/2
inhibition within tumor tissues and PSA reductions in 15% of patients (NCT02064608), although
the development of this small-molecule inhibitor has since been discontinued [240]. A clinical trial
investigating the dual mTORC1/2 inhibitor sapanisertib in patients with mCRPC was also closed early
due to suspected AR activation in response to treatment, and little clinical response was observed
(largely due to dose-limiting toxicity and tolerance) (NCT02091531) [39]. Thus, further exploration into
the tumor biology and to the mode of action of mTORC1/2 inhibitors is needed to discover efficacious
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approaches for these small-molecule inhibitors, either as single agents or in combination with current
treatment regimens.
So far, much of the clinical focus towards mTOR inhibition has revolved around sirolimus
(rapamycin) and its analogues everolimus (RAD001) and temsirolimus (CCI-779). However,
despite showing good tolerability profiles when used alone or combined with other treatments,
little anti-tumor activity has been reported in the clinic [40–42,241–249]. Efforts to improve the
bioavailability and performance of these agents through nanoparticle encapsulation and binding are
ongoing, although whether this improves their anti-tumor effects remains to be determined [250,251].
Nonetheless, early reports from a separate study have indicated promising responses in patients with
PTEN-deficient mCRPC (NCT00976755). In this small phase 2 study, PTEN loss was predictive of
response in chemotherapy naïve mCRPC patients treated with the mTORC1 inhibitor everolimus daily,
with PFS in PTEN-deleted patients improved compared to unselected patients [252]. Furthermore,
a recent case study involving a patient with a PTEN inactivating mutation treated with everolimus
showed prolonged disease stabilization after previously failing rounds of bicalutamide, docetaxel,
abiraterone, and cabazitaxel treatment [253]. Interestingly, the combination of everolimus alongside
bicalutamide has shown some encouraging clinical responses in bicalutamide-naïve CRPC patients,
but not in those with prior exposure to the drug [254,255]. Further clinical exploration is planned
to test the use of everolimus alongside other androgen/AR-directed therapies such as apalutamide
(NCT02106507) and enzalutamide (NCT02125084). However, patients will not be selected via genetic
status prior to treatment. It will therefore be interesting to see whether findings from these trials
also reveal a correlation between response and PTEN deficiency (or any other PI3K–AKT–mTOR
pathway genetic drivers). Interestingly, a clinical trial involving everolimus in patients with CRPC that
have a genetic alteration in the PI3K–AKT–mTOR pathway (identified by next-generation sequencing)
is ongoing (NCT03580239). This approach will gain further insight into the value of everolimus as
a precision medicine to target PTEN-deficient prostate cancer.
3.5. Approaches to Enhance the Efficacy of PI3K–AKT–mTOR-Directed Therapy
Various mechanisms of intrinsic and acquired resistance to PI3K–AKT–mTOR-directed
therapies have been identified that prevent complete suppression of the pathway, such as
feedback loops and redundancy within the cascade, which could be targeted to increase drug
sensitivity [211,212]. For instance, increased activity of kinases that act in a redundant fashion to
regulate AKT-mediated downstream effector cascades (e.g., mTORC1) can facilitate tumor cell resistance
to AKT inhibition [180,206,256,257]. Interestingly, one study has reported that AKT-independent
activation of mTORC1 following AKT inhibition can be overcome by combining AKT and mTORC1
inhibitors in a PTEN-deficient prostate cancer transgenic mouse model [206], supporting the concept
of vertically targeting the PI3K–AKT–mTOR pathway to prevent drug resistance associated with
PI3K–AKT–mTOR-directed monotherapies [180]. Below, we discuss several current approaches being
explored to overcome resistance to PI3K–AKT–mTOR-targeted therapies.
3.5.1. SGK Inhibition
SGKs, which belong to the same family of AGC (protein kinase A/protein kinase G/protein
kinase C) serine/threonine kinases as AKT, are becoming increasingly recognized as an important
PI3K downstream effector family of kinases [258]. The SGK family is comprised of SGK1, SGK2 and
SGK3 isoforms, which are activated through PDK1 and mTORC2 phosphorylation in a similar
manner to AKT [259,260]. However, SGKs can act independently to AKT to direct AKT-mediated
signaling events through the regulation of shared downstream substrates [258]. Consequently, they are
also susceptible to hyperactivation following PTEN loss and can contribute to tumor growth [190].
However, the relationship between SGKs and PTEN status in prostate cancer is yet to be fully established.
Compensatory activation of AKT downstream targets (including mTORC1 in breast and colorectal
cancer cell lines) by SGK1 has been observed in response to AKT blockade, suggesting that SGKs
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may mediate AKT-driven tumorigenic processes in the presence of an AKT inhibitor [258,261–263].
Interestingly, breast cancer cell lines resistant to the AKT inhibitors capivasertib and MK-2206 express
high levels of SGK1 and are sensitive to SGK knockdown (KD) [264], while sustained AKT inhibition
leads to increased SGK3 expression that can replace AKT-mediated activation of mTORC1 [257].
Furthermore, SGK1/SGK3 are amplified in up to 3% and 20% of prostate cancer cases, respectively [144],
and SGK1 has been identified as an AR-regulated target gene [256]. Significantly, SGK1 inhibition is
reported to reduce prostate cancer cell line proliferation and invasive potential, and can synergize
with the mTOR inhibitor rapamycin in vitro [256,265]. In vivo preclinical studies have also shown that
SGK1 KD in PC-3 xenografts significantly reduces tumor burden and metastatic potential compared to
controls [265], and combining SGK and AKT inhibitors (e.g., 14h and MK-2206) is synergistic in both
breast and thyroid cancer models [257,266,267]. These data suggest that dual inhibition of both AKT
and SGK could be an effective therapeutic approach to overcome AKT inhibitor resistance. However,
SGK inhibitors are yet to advance into clinical trials.
3.5.2. PKC Inhibition
In addition to SGKs, the PKC superfamily of isoenzymes presents another set of PI3K downstream
effector proteins that can also be regulated by mTORC2 [268]. Three subfamilies of PKCs exist which
are classified as either conventional (α, βI, βII, and γ), novel (δ, ε, η, and θ) or atypical (ζ, µ, and λ/ι)
depending on their lipid-activation profiles, although each member can be activated by PIP3 in the
presence of PKC co-factors [189,269–271]. The role of these isoenzymes in cancer progression remains
controversial, with several members shown to mediate both pro-tumorigenic and tumor-suppressive
functions (reviewed in [272]). This is highlighted by the atypical PKC member PKCζ that can mediate
both pro- and anti-tumorigenic responses in prostate cancer [273–276]. Genetic inactivation of PRKCZ
that encodes PKCζ facilitates invasive prostate carcinoma progression in Pten+/− mice, indicating that
PKCζ is a tumor suppressor in the context of PTEN deficiency [275]. However, contradictory to this,
a reduction in tumor growth and metastatic burden has been observed following PKCζ suppression in
PC-3 xenografts, attributable in part to impaired AKT signaling [277]. Interestingly, overexpression
of the pro-oncogenic kinase and novel PKC member PKCε can also promote prostate epithelial cell
growth and invasion in Pten heterozygous transgenic mouse models, associated with NF-κB activation
and COX-2 upregulation [278,279]. In support, treatment with either the Cox-2 inhibitor rofecoxib or
the NF-κB inhibitor parthenolide significantly abrogated tumor growth of a xenograft model using
PTEN-null prostate epithelial murine cells engineered to overexpress PKCε relative to control mice [279],
and long-term rofecoxib administration in a transgenic Pten+/− mouse conditionally overexpressing
PKCε in the prostate epithelium inhibited tumor formation [279]. These findings build upon previous
work showing that shRNA-mediated PKCε KD in a highly metastatic clone of PC-3 cells could
inhibit metastatic dissemination to the bone in vivo [280]. In vitro invasion assays have also revealed
PKCε silencing or treatment with the PKCε inhibitor εV1-2 impairs invasive potential [280]. Thus,
although our molecular understanding of the role of PKCs in prostate cancer is limited, these studies
provide key evidence that targeting specific PKC isoenzymes may hold therapeutic promise.
3.5.3. GTPase Inhibition
The Rho family of small GTPases including RAC proteins (RAC1, RAC2 and RAC3) and CDC42
are important mediators of cell cytoskeletal rearrangements that regulate cell migration and
metabolism [281,282]. Small GTPase activity is governed by guanine nucleotide exchange factors (GEFs),
which convert inactive GDP-bound GTPases into an activated GTP-bound state. This process is
tightly controlled by upstream regulatory networks, including AKT-independent PIP3-mediated PI3K
signaling [191,283]. Interestingly, both RAC and CDC42 can directly activate p110β by directly binding
to its RAS-binding domain (RBD), and RAC1 activity has also been shown to be regulated by p110β in
a PTEN-deficient mouse model of hematological cancer [284,285]. We have also previously shown
that PTEN-deficient prostate cancer growth is at least partly driven through p110β-RAC1 activation
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in vivo [21]. Hyperactivation of RAC1 and CDC42 in response to PTEN loss has also been linked
to increased cell motility in mouse fibroblasts [286], possibly linked to PTEN’s ability to suppress
PIP3-dependent Rac exchanger 2 (PREX2) activity, a GEF that activates RAC1 to promote cell migration
and invasion [287]. Thus, the p110β-RAC1 signaling axis may have important therapeutic implications
for PTEN-deficient prostate cancer.
Both RAC1-specific and dual RAC1/CDC42 inhibitors (NSC23766 and AZA1, respectively)
have shown preclinical efficacy in prostate cancer cell lines (including PTEN-null PC-3 cells),
inhibiting both cell migration and in vivo tumor growth [288,289]. In support, siRNA silencing
of RAC/CDC42 regulating GEFs, such as PIP3-dependent Rac exchanger 1 (PREX1) and vav guanine
nucleotide exchange factor 3 (VAV3), can significantly reduce prostate cancer cell proliferation and
migration in vitro [290,291]. Furthermore, exogenous expression of PREX1 in CWR22Rv1 human
mCRPC cells that have limited metastatic potential in vivo caused spontaneous lymph node metastasis
in mice, with no effect on primary tumor growth [290]. Thus, inhibition of GTPase–GEF interactions
presents an attractive avenue for therapeutic intervention, particularly as an anti-metastatic approach.
The small-molecule inhibitor ZCL278 that blocks CDC42–intersectin (ITSN) interactions and its
more potent analogue ZCL367 that also inhibits RAC1 have shown preclinical promise in prostate
cancer [292,293]. This includes their ability to inhibit cell proliferation and migration in a variety of
prostate cancer cell lines including PC-3 (PTEN−/−) and DU145 (PTEN+/−) cells in vitro, and ZCL367
is also reported to significantly inhibit tumor growth in a xenograft model of lung cancer [292].
Intriguingly, both RAC1 activity and CDC42 activity have been associated with therapeutic resistance
in different cancer types, including enzalutamide resistance in CRPC, and RAC/CDC42 inhibition
has been suggested as a potential approach to overcome resistance to PI3K–AKT–mTOR-targeted
treatments [294–298]. Although RAC/CDC42-specific inhibitors remain to be explored clinically,
one FDA-approved non-steroidal anti-inflammatory drug (NSAID), R-ketorolac, has been shown to
potently inhibit RAC1 and CDC42, and has been demonstrated to improve ovarian cancer patient
survival (NCT02470299), suggesting that GTPase targeting could be efficacious in other human cancers
with elevated expression and activity of RAC1 and/or CDC42 [299].
3.5.4. AXL Inhibition
The RTK AXL (tyrosine-protein kinase receptor UFO) has been heavily implicated in various
aspects of tumorigenesis in several cancer types, and is overexpressed in prostate cancer [300,301].
AXL makes up part of the TAM family of receptors that also includes TYRO3 protein tyrosine
kinase (TYRO3) and MER proto-oncogene tyrosine kinase (MER), which promote cell proliferation,
migration and survival in response to upstream activation via extracellular growth factors, such as
growth arrest-specific protein 6 (GAS6) [302]. In prostate cancer, GAS6-AXL signaling has been
shown to promote proliferation by inducing AKT and mitogen-activated protein kinase (MAPK)
phosphorylation [303]. In addition, GAS6-mediated activation of AXL has been shown to promote EMT
and cell migration in DU145 cells, and can protect PC-3 cells from undergoing chemotherapy-induced
apoptosis [304,305]. AXL activation has also been shown to initiate a dormant state in prostate cancer
cells. However, the importance of AXL in maintaining long-term dormancy and its role during
metastasis have been debated in recent follow-up work [305,306].
AXL signaling has also been implicated in promoting resistance to PI3K–AKT–mTOR
pathway-directed therapy in various settings. For instance, AXL-mediated activation of mTORC1
signaling through PKC has been shown to promote acquired resistance to the p110α inhibitor
BYL719 in squamous carcinoma cell lines in vitro and in vivo, while AXL activation has also been
observed in an oesophageal cancer cell line resistant to AKT inhibition [307,308]. Interestingly,
AXL is upregulated and activated in docetaxel-resistant prostate cancer cell lines, and AXL
blockade in these cells, either by siRNA targeting or treatment with the non-specific tyrosine kinase
inhibitor amuvatinib (MP470), induced apoptosis and reduced cell migration and invasion [309].
Amuvatinib treatment also suppressed tumor growth in a docetaxel-resistant prostate cancer xenograft
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model, and significantly enhanced the efficacy of docetaxel [309]. This inhibitor has been tested clinically
in advanced solid cancers in combination with different chemotherapeutics and appears to be well
tolerated, with anti-tumor benefits reported, particularly in lung neuroendocrine tumors, and stable
disease was observed in three of the four prostate cancer patients recruited (NCT00881166) [310].
Combining amuvatinib and the epidermal growth factor receptor (EGFR) inhibitor erlotinib has also
been shown to significantly inhibit tumor growth in PTEN-null LNCaP xenografts, accompanied by
reduced AKT phosphorylation at S473 and T308 [311]. Several more specific inhibitors have also been
developed that target both the AXL receptor directly and its ligand GAS6, including bemcentinib
(BGB324) [312]. This inhibitor was also shown to induce apoptosis in docetaxel-resistant prostate
cancer cell lines in vitro, at least partly through reducing levels of phosphorylated AKT, and was also
able to partially rescue an EMT phenotype driven through docetaxel resistance [309]. In addition to
the pro-tumorigenic role of AXL on tumor cells, AXL signaling can also suppress anti-tumor immune
responses. Therefore, these inhibitors may advantageously play a dual role both directly killing cancer
cells and improving immune cell-mediated killing [313].
Clinical trials are now testing bemcentinib in several cancers and early data suggest that it is
well tolerated. However, to date, no trials have investigated its efficacy in prostate cancer [312,314].
Although little work has explored the role of AXL inhibition within the context of PTEN status,
one study has shown that selective cytotoxic responses are achieved in PTEN-deficient glioblastoma
cells when S6K1 inhibitor LY-2779964 is combined with AXL/TAM kinase inhibitor BMS-777607 or TAM
kinase KD, suggesting that the combined targeting of S6K1 and TAMs could be a potential strategy for
treatment of PTEN-deficient tumors [315]. In contrast, AXL inhibition in BRAF mutant melanoma may
be more effective in PTEN wild-type patients, as phosphorylated AXL is only significantly increased in
BRAF inhibitor-resistant cell lines in the context of endogenous PTEN [316]. Therefore, while preclinical
data indicate that AXL is a promising therapeutic target, particularly within docetaxel-resistant disease,
more research is required to establish the role of AXL activation in prostate cancer, and to determine
whether PTEN status is a predictive marker for AXL activity. Given the clear association between AXL
signaling and drug resistance, including PI3K–AKT–mTOR pathway inhibitors, future work exploring
AXL inhibitors could also provide new insights into how therapeutic resistance can be overcome.
4. PTEN and the DNA Damage Response
DNA damage events are common and may result from both endogenous processes, such as
errors occurring during DNA replication and metabolic stress, and exogenous sources, such as
ionizing radiation, drugs and toxins [317]. In order to maintain genomic integrity and prevent
tumorigenesis, cells have developed a range of complex mechanisms to detect DNA damage and
initiate a series of downstream effector cascades that, together with the action of cell cycle checkpoints,
culminate in either cell cycle arrest, targeted repair/bypass of the damage or, if the former are not
possible, cell death or senescence [318]. Collectively, these mechanisms are known as the DNA
damage response (DDR), of which five main pathways have been described. Base excision repair
(BER) corrects small base lesions such as modified bases at basic sites and DNA single-strand breaks
(SSBs) that arise as a consequence of deamination, oxidation or alkylation caused by chemicals,
ionizing radiation and spontaneous DNA decay [319]. Nucleotide excision repair (NER) acts to remove
a number of structurally unrelated DNA lesions, such as 6-4 pyrimidine-pyrimidone photoproducts
(induced by UV radiation), bulky chemical adducts and intrastrand crosslinks. Mismatch repair (MMR)
corrects DNA base–base mismatches that arise during normal DNA metabolism or aberrant DNA
processing during replication, recombination and repair [320]. Homologous recombination repair
(HRR) is one of two major repair mechanisms for DNA double-strand breaks (DSBs), highly toxic
lesions that are induced by replication errors, ionizing radiation and chemicals [321]. The process of
HRR comprises a series of interconnected pathways that, through the use of the sister chromatid as
a template, culminate in the error-free restoration of the original DNA code [322]. Non-homologous end
joining (NHEJ) is the other major repair mechanism for DSBs. Unlike HRR, NHEJ mechanisms do not
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utilize a homologous template and therefore occur during all phases of the cell cycle, rather than being
restricted to S and G2 phases alone [323]. The lack of template renders classical NHEJ error prone,
which in turn can lead to DNA rearrangements that may drive genomic instability and oncogenic
transformation [324].
Whilst originally considered to be a cytoplasmic protein, PTEN is now known to also localize to the
nucleus and associate with centromeres, where it can exert several functions, including maintenance of
chromosomal integrity and regulation of the DDR [325]. Previous work has shown that bi-allelic deletion
of Pten in mouse embryonic fibroblasts (MEFs) induces spontaneous DNA DSBs, thereby indicating
that PTEN plays a role during DSB repair and genomic stability [17]. In this study, transcription of
RAD51 (that encodes a protein vital to DSB repair via HRR) was significantly reduced in Pten-null
MEFs while enforced expression of RAD51 restored DSB repair, suggesting that PTEN regulates DSB
repair through transcriptional regulation of RAD51 [17]. In support, ectopic expression of PTEN in
human PTEN-null PC-3 CRPC cells induced RAD51 transcription and RAD51 protein expression,
and reduced the number of DSBs [17]. However, although an independent study also revealed that
PTEN depletion in DU145 mCRPC cells causes increased DNA DSBs and reduces HRR following
irradiation, no significant correlation between RAD51 protein level and PTEN status was detected
in a large radical prostatectomy tissue microarray (TMA) (n > 1500) [326]. Similar non-correlative
findings have also been reported in a separate primary prostate cancer TMA, and further work has
shown that RAD51 recruitment to DSBs in prostate cancer cells in response to UV irradiation is not
impeded by PTEN deficiency [327]. These conflicting findings indicate that whilst it is clear PTEN
plays a role in the repair of DSBs via HRR, further research is needed to elucidate the exact molecular
mechanisms and pathways involved.
PTEN has also been implicated in cell cycle regulation through interactions with cyclin D1 and
checkpoint kinase 1 (CHK1, or CHEK1), both of which play crucial roles in cell cycle checkpoint
activation to facilitate DNA damage recognition and repair. For example, siRNA-mediated KD of PTEN
in DU145 cells has been shown to diminish CHK1 activation in response to UV and X-ray irradiation,
with a resulting reduction in cell cycle arrest at the G2/M checkpoint [326]. Interestingly, this effect
appears to be mediated via AKT, which can phosphorylate CHK1 at S280, resulting in reduced CHK1
nuclear localization and hence impaired checkpoint activation that can be rescued following AKT
inhibition [326]. As AKT-dependent phosphorylation of CHK1 is increased in PTEN-depleted cells,
these findings indicate that PTEN exerts its cell cycle activity through the regulation of AKT activity,
and the subsequent phosphorylation and CHK1 cytoplasmic sequestration [326,328]. In addition to
DSB repair and cell cycle regulation, PTEN is also reported to be essential for the efficient repair of UVB
related DNA damage products such as pyrimidine(6-4)pyrimidone dimers via the process of NER [329],
suggesting that PTEN is involved in multiple arms of the DDR. This adds further complexity to the
range of PTEN nuclear tumor-suppressive functions and may in turn indicate a role for DDR-targeting
treatment strategies in patients with aberrations in PTEN.
In preclinical pharmacological studies, PTEN loss has been shown to increase sensitivity to
DDR-targeting agents such as poly-ADP ribose polymerase (PARP) inhibitors in a range of cancer cell
lines, and in the PTEN-null colorectal cancer HCT116 xenograft model [330]. However, studies in
the setting of PTEN-deficient prostate cancer have been conflicting. Whilst an early report did not
demonstrate a relationship between decreased PTEN expression and sensitivity to PARP inhibition
in metastatic prostate cancer cell lines in vitro [327], a more recent study reported that PTEN KD in
DU145 cells increases sensitivity to the PARP inhibitor olaparib (AZD2281) when compared with
control cells [326]. Furthermore, whilst two early phase clinical trials involving patients with heavily
pretreated CRPC have not demonstrated a correlation between PTEN loss and response to PARP
inhibition [331,332], patient numbers were low and therefore larger-scale studies are required to further
delineate the relationship between PTEN status and PARP inhibitor sensitivity in the clinic.
Whilst the jury remains out on whether PTEN loss confers increased sensitivity to PARP inhibitors,
it is generally considered that PARP inhibition results in increased AKT pathway activation as a form
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of cytoprotective response in a variety of disease model systems [333–336]. Additionally, as discussed
above, AKT-dependent phosphorylation and cytoplasmic sequestration of CHK1 appears to be
enhanced in PTEN-deficient cells, indicating that PTEN controls the G2/M cell cycle checkpoint through
its regulation of AKT activity [326,328]. Taken together, these findings indicate that combination
therapy with a PI3K–AKT–mTOR pathway inhibitor in patients with advanced prostate cancer may
overcome the cytoprotective effects of PARP inhibitor-induced AKT activation, perhaps with additional
benefit in those with PTEN deficiency and increased AKT signaling. Whilst preclinical studies and early
phase clinical trials have demonstrated promise for combined PARP and PI3K–AKT–mTOR pathway
blockade in patients with both HRR-proficient and -deficient cancers (determined by functional status
of breast cancer susceptibility protein 1 and 2, BRCA1 and BRCA2) [337–341], it has not yet been
explored in prostate cancer specifically. However, a phase I/II trial evaluating the safety and efficacy
of the AKT inhibitor ipatasertib in combination with the PARP inhibitor rucaparib in patients with
advanced breast, ovarian and prostate cancer is currently recruiting and should provide invaluable
insight into the efficacy of this combination in the setting of advanced prostate cancer (NCT03840200).
5. PTEN and the Tumor Microenvironment
Studies addressing the complex relationship between tumor cells and components of the TME
(e.g., various cancer-associated fibroblast populations, smooth muscle cells, structural matrix factors,
vasculature, nerve cells and the immune cell infiltrate) have revealed that the TME can influence
tumor cell behavior at every stage of tumorigenesis, from tumor initiation through to metastatic
progression [342–344]. The generation of new and improved models to study the TME has informed
and facilitated the development of new therapeutics that target different TME components, and aided
the discovery of predictive biomarkers within the TME that may be used to guide personalized
treatment decisions [345]. PTEN represents one such biomarker that has been shown to influence
the behavior of several components of the TME in different cancer types including prostate cancers,
discussed below.
5.1. PTEN and Tumor–Stroma Interactions
Communication between the prostate epithelial cells and the surrounding stroma is crucial
for prostate organogenesis and the maintenance of normal adult tissue homeostasis, and has been
shown to play a key role during ageing and prostate tumorigenesis [343]. Although the majority
of anti-cancer therapeutics specifically target the tumor cells, TME components can promote tumor
cell resistance to these agents, as tumor–stroma interactions (TSIs) have been shown to influence
both tumor growth rates and treatment responses, including in the context of radiotherapy, surgery,
chemotherapy and immunotherapy [344,346–351]. For instance, the physical interaction of breast
cancer cells and mesenchymal stem cells can confer resistance to trastuzumab in vitro by activation of
non-receptor tyrosine kinase c-SRC and PTEN downregulation [351], and analysis of a prostate cancer
TMA has revealed that stroma volume and altered expression of desmin and smooth muscle α-actin are
each independent and significant predictors of biochemical recurrence [352]. In addition, resistance to
EGFR inhibition is reported to be caused by hepatocyte growth factor (HGF) secretion by fibroblasts in
triple-negative breast cancer, which activates EGFR-MET crosstalk [353], while the co-culture of prostate
cancer cell lines with cancer-associated fibroblasts (CAFs) can mediate resistance to the multityrosine
kinase inhibitor sorafenib [354]. Although the functional consequence of PTEN loss in prostate epithelial
cells and its role during prostate cancer progression have been well characterized, the tumor-suppressive
role of PTEN in the prostate TME remains unclear. Intriguingly, increased extracellular matrix stiffness
has been shown to induce miR-18a expression to reduce PTEN levels by downregulating homeobox A9
(HOXA9) in human and mouse breast cancer tissue, and matrix stiffness and high miR-18a expression
can predict for poor prognosis in patients with luminal breast cancers [355]. Whether a similar
association occurs in prostate cancer remains to be determined.
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PTEN loss in tumor cells can also result in remodeling of the stromal compartment in prostate
cancer [356]. Conditional Pten homozygous deletion in the prostate epithelium of castrated mice
is reported to loosen areas of surrounding smooth muscle actin and promote collagen deposition,
increasing invasive potential [356]. Interestingly, deletion of Pten in stromal fibroblasts within the
murine mammary gland has been shown to initiate significant extracellular matrix (ECM) remodeling,
resulting in mammary tumor initiation and invasive progression through alterations in collagen
alignments [357,358]. These findings indicate that PTEN can elicit its tumor-suppressive function
through stromal fibroblasts and raise the possibility of a similar role in other epithelial cancers.
Although stromal-specific deletion of Pten has not been assessed in the prostate, p62 deletion in this
compartment leads to metabolic reprogramming of prostate stromal fibroblasts, inactivating the
p62/mTORC1/c-Myc signaling network that promotes inflammation and tumorigenesis [359].
Ultimately, these findings illustrate the need for further research to investigate how PTEN loss promotes
pro-tumorigenic prostate TSIs, ECM remodeling and an immunosuppressive microenvironment during
prostate tumorigenesis and in response to therapeutic intervention.
5.2. PTEN and the Immune Response
Loss of the tumor suppressor PTEN in both epithelial or surrounding stromal/immune cells
can also have an overall immunosuppressive effect on the TME via multiple direct and indirect
mechanisms [360,361]. For example, intrinsic PTEN loss in established melanoma cell lines and
patient-derived cells has been shown to promote PI3K-mediated activation of immunosuppressive
cytokines [362]. Similarly, in silico screening of infiltrating immune cells from 741 primary and
96 metastatic clinical prostate cancer samples linked PTEN deficiency with an immunosuppressed
TME [363]. Furthermore, activation of the JAK2/STAT3 pathway resulting in an immunosuppressive
TME has been reported in senescent PTEN-null prostate tumors, which supports tumor growth and
chemoresistance [364]. Although not well characterized in prostate cancer specifically, direct PTEN
loss in several immune cell types, including regulatory T cells, natural killer cells and macrophages,
has also been demonstrated to shift the TME to an immunosuppressive state in various cancer models
(reviewed in [360,361]).
The enhanced immunosuppressive TME associated with PTEN-deficient prostate tumors
is likely to have important clinical implications, especially in the context of immunotherapy.
Several immunotherapies are already being used in the clinic to treat patients with metastatic
prostate cancer, including the immune boosting vaccine sipuleucel-T and the PD-1 checkpoint inhibitor
pembrolizumab [365]. Both approaches have demonstrated therapeutic efficacy in a subset of patients.
However, further research is needed to identify which patients are most likely to benefit [366,367].
Although the implications of PTEN loss and response to these treatments in the context of prostate
cancer is yet to be evaluated, preclinical and clinical data from other cancer types are beginning to reveal
that PTEN loss may desensitize patients to immunotherapy [360,368–371]. For example, PTEN-deficient
melanoma is associated with a poor response to PD-1 inhibitors pembrolizumab and nivolumab that
is reported to reflect reduced T-cell tumor infiltration and activity [369]. Interestingly, combining an
anti-mouse PD-1 antibody and the p110β isoform-specific inhibitor GSK2636771 significantly reduced
tumor growth and survival relative to monotherapy in Braf -mutant, Pten-null melanoma in vivo,
and was associated with increased T-cell infiltration [369]. A similar response has been observed in the
same model when combining GSK2636771 and an anti-OX40 targeting antibody [372]. This preclinical
work has led to an ongoing clinical trial (NCT03131908) assessing the safety and efficacy of checkpoint
inhibition combined with GSK2636771 in PTEN-deficient metastatic melanoma. Current reports,
however, indicate that a phase II arm of this study assessing the treatment of other solid cancers
(including prostate cancer) has been discontinued, possibly owing to early data revealing dose-limiting
renal toxicities [373]. Despite this, efficacy data from this study may still inform the design of future
clinical trials investigating a similar treatment combination in PTEN-deficient cancer.
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5.3. PTEN and Inflammation
Intra-prostatic inflammation is another microenvironmental factor that has been associated with
prostate cancer initiation and progression [374–377]. Exposure of normal prostate epithelium to various
internal and external stresses can trigger an initial inflammatory response which ultimately results in
a self-propagating cycle that leads to chronic inflammation (reviewed in [377]). This is maintained
by various cell types in the TME including myeloid-derived suppressor cells (MDSCs), TAMs and
the prostate epithelial cells themselves [378–382]. Interestingly, deletion of Pten in murine prostate
epithelial cells has been shown to upregulate inflammatory-associated gene expression resulting
in the immediate expansion of intraprostatic MDSCs and sustained immune suppression [383].
Furthermore, siRNA and shRNA suppression of PTEN in DU145 and 22Rv1 prostate cancer cell lines
has also been shown to upregulate CXCL8 mRNA that encodes the proinflammatory chemokine
interleukin 8 (IL8) [384]. This response was enhanced in hypoxic conditions and was also replicated in
prostate tissue from mice with heterozygous Pten deletion [384]. Co-culture experiments in vitro have
also shown that upregulation of CXCL8 following PTEN-loss can potentiate additional chemokine
expression in an autocrine and paracrine manner on surrounding stromal cells to further promote
prostate tumor progression and invasion [385]. Importantly, the relationship between PTEN loss
and CXCL8 upregulation has been validated in clinical prostate samples and could potentially be
exploited therapeutically by targeting cellular inhibitor of apoptosis protein-1 (cIAP-1). cIAP1 is
an anti-apoptotic protein that is upregulated in prostate cancer cells following CXCL8-mediated
TAM infiltration, and cIAP1 inhibition has been shown to be effective in PTEN-depleted DU145 Sh11.02
cells in vitro [84].
Upregulation of CXCL8 is also a hallmark of the senescence secretory response, known as the
senescence-associated secretory phenotype (SASP), which follows senescence induction and has been
shown to promote therapeutic resistance in men with prostate cancer [386]. Of note, PTEN loss
in prostate cancer cells is also known to induce a p53-dependent senescent phenotype [387,388].
Significant evidence in the literature has identified that DNA-damaging agents promote senescence
in both cancer cells, and surrounding non-malignant cells in the TME [389], while senescent CAFs
in prostate cancer have been shown to secrete SASP-related factors to promote tumor cell survival,
growth and migration post-chemotherapy and radiotherapy [390,391]. Interestingly, mTOR has been
shown to regulate this secretory response [392] and consequently, mTOR inhibition in combination with
chemotherapy or radiotherapy may suppresses this secretory program and its ability to promote tumor
growth. PTEN-deficient induced senescence in prostate tumors can also promote the growth of adjacent
non-senescent tumor cells, and cause chemoresistance through a SASP-associated mechanism [364].
The development of selective agents that eliminate senescent cells (senolytics) and SASP-modulating
agents (senostatics) could therefore potentiate the anti-tumor effects of senescence driven by PTEN-loss
in fibroblasts by reducing the pro-tumorigenic effects associated with the upregulation of SASP [393].
Finally, accelerated prostate cancer progression has also been associated with inflammation caused
by a high-fat diet in PTEN-deficient prostate cancer mouse models, suggesting that alterations to
patient diet and/or exercise regimens may be especially beneficial for those with PTEN-deficient
disease [394–396]. Although the clinical data available are still not clear on which nutrients may offer
the most protection, switching to a ketogenic diet which encourages the body to burn fat may prove to
be a beneficial approach [217]. Additional work in mouse models has also demonstrated that this diet or
pharmacological suppression of blood glucose levels can improve sensitivity to PI3K pathway inhibition
through the inhibition of PI3K-mediated insulin feedback, which could be an interesting approach for
PTEN-deficient prostate cancer [217]. In summary, while current evidence in the literature has clearly
identified that PTEN plays a tumor-suppressive role in epithelial and stromal cells, additional work is
needed to better understand the molecular mechanisms underlying PTEN regulation of the TME and
to discover how this can be effectively exploited to treat PTEN-deficient cancers.
Cells 2020, 9, 2342 24 of 48
6. Conclusions
Loss of the tumor suppressor PTEN is a frequent event in prostate cancer that contributes
to tumor growth and therapeutic resistance through oncogenic PI3K–AKT–mTOR signaling,
increased genomic instability, impaired DNA damage repair, pro-tumorigenic reprograming of
the tumor microenvironment and immunosuppression. Substantial research efforts addressing
the underlying molecular biology of prostate cancer continue to define the tumor-suppressive
function of PTEN and have resulted in major advances in targeting PTEN-deficient prostate cancer.
Promising treatment options include both direct and indirect approaches to restore PTEN function,
and PI3K–AKT–mTOR blockade in combination with either chemotherapy, androgen/AR-directed
agents, DDR inhibitors, immuno-oncology drugs or additional PI3K–AKT–mTOR-directed therapies
that may enhance therapeutic efficacy through diverse synergistic and complementary mechanisms.
New PI3K–AKT–mTOR inhibitors with increased potency and selectivity also offer promise,
and next-generation delivery systems are also under investigation as precision anti-cancer modalities.
However, the clinical evaluation of these approaches is needed to determine the most effective,
well-tolerated treatment strategy for PTEN-deficient prostate cancer. Recent findings indicate that
PTEN status (and perhaps other genetic drivers of the PI3K–AKT–mTOR pathway) offers an invaluable
opportunity to guide treatment decisions that improve the clinical management of this patient
population during both the early and advanced stages of this disease. A key question that remains
unanswered is whether patients with PTEN-deficient low-risk localized prostate cancer would
benefit from radiotherapy and/or surgery. To address this, future clinical investigations that include
establishing PTEN status at diagnosis are needed. Nevertheless, exploiting the predictive value of PTEN
to improve patient care will rely on accurate, stringent testing for PTEN activity, and consideration
of the disease subtype, the mechanism by which PTEN has been lost, the co-occurrence of other
oncogenic PI3K–AKT–mTOR alterations with PTEN loss and the extent of tumor heterogeneity is
paramount. While advances in artificial intelligence-based algorithms, digital spatial profiling, and
the generation of new clinically relevant models of prostate cancer that span a range of different
disease subtypes are beginning to address these points, the continued exploration into PTEN function,
PI3K–AKT–mTOR inhibition and prostate cancer biology is essential for the identification of new
therapeutic approaches and valuable predictive biomarkers that will help to refine future personalized
therapies for PTEN-deficient prostate cancer.
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4EBP1 4E (eIF4E)-binding protein 1
AMO Antisense anti-miR oligonucleotide
AR Androgen receptor
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Cas9 CRISPR-associated protein 9,
CHK1 Cyclin D1 and checkpoint kinase 1
cIAP-1 Cellular inhibitor of apoptosis protein-1
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EGFR Epidermal growth factor receptor
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FOXO Forkhead box protein O
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GSK3β Glycogen synthase kinase 3 beta
GPCR G-protein coupled receptor
HER2 Human epidermal growth factor receptor 2
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MAPK Mitogen-activated protein kinase
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MDSC Myeloid-derived suppressor cells
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mpMRI Multiparametric MRI
mTOR Mammalian target of rapamycin
mTORC1 Mammalian target of rapamycin complex 1
mTORC2 Mammalian target of rapamycin complex 2
NER Nucleotide excision repair
NF-κB Nuclear factor kappa light chain enhancer of activated B cells
NHEJ Non-homologous end joining
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OncomiRs Oncogenic miRNAs
P Phosphorylation event
PBD PIP2-binding domain
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PDK1 Phosphoinositide-dependent kinase 1
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Phos D Phosphatase domain
PI3K Phosphoinositide 3-kinase
PIP2 Phosphatidylinositol 4,5-bisphosphate
PIP3 Phosphatidylinositol 3,4,5-trisphosphate
PKB Protein kinase B, AKT
PKC Protein kinase C
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PREX2 PIP3-dependent Rac exchanger 2
PSA Prostate-specific antigen
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RBD Ras-binding domain
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rPFS Radiographic progression-free survival
RFS Recurrence-free survival
RTK Tyrosine kinase receptor
S6K Ribosomal protein S6 kinase/p70 ribosomal S6 kinase
SGK1 Serum- and glucocorticoid-regulated kinase 1
SGK2 Serum- and glucocorticoid-regulated kinase 2
SGK3 Serum- and glucocorticoid-regulated kinase 3
siRNA Small interfering RNA
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SRC-3 Steroid receptor co-activator 3
SSBs Single-strand breaks
TAM Tumor-associated macrophage
TSC1 Tuberous sclerosis complex 1
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